Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)

6 Oct 2005

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 16213151
DOI: 10.1016/j.critrevonc.2005.06.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)PMID 16213151Read ↗

Specific Targeted Therapy of Chronic Myelogenous Leukemia with ImatinibSemantic proximity Read ↗

Therapeutic targets in chronic myeloid leukaemiaSemantic proximity Read ↗

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?Semantic proximity Read ↗

Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patientsSemantic proximity Read ↗

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapiesSemantic proximity Read ↗

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistanceSemantic proximity Read ↗

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemiaSemantic proximity Read ↗

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Treating imatinib-resistant leukemia: the next generation targeted therapies.Semantic proximity Read ↗

Targeted CML therapy: controlling drug resistance, seeking cureSemantic proximity Read ↗

Imatinib resistance in CMLSemantic proximity Read ↗

Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.